For research use only. Not for therapeutic Use.
Bersacapavir（Cat No.:I023290）is an investigational antiviral agent designed to target and inhibit hepatitis B virus (HBV) replication. It belongs to a novel class of capsid assembly modulators, disrupting the virus’s life cycle by interfering with the formation of its protective capsid structure. This mechanism has shown promise in reducing HBV DNA levels, offering potential as a key component in functional cure strategies. With a favorable pharmacokinetic profile and oral bioavailability, Bersacapavir is under clinical evaluation for its efficacy and safety, representing a significant advancement in chronic HBV treatment research.
| Catalog Number | I023290 |
| CAS Number | 1638266-40-6 |
| Synonyms | Bersacapavir |
| Molecular Formula | C16H14F4N4O3S |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| IUPAC Name | N-(3-cyano-4-fluorophenyl)-1-methyl-4-[[(2S)-1,1,1-trifluoropropan-2-yl]sulfamoyl]pyrrole-2-carboxamide |
| InChI | InChI=1S/C16H14F4N4O3S/c1-9(16(18,19)20)23-28(26,27)12-6-14(24(2)8-12)15(25)22-11-3-4-13(17)10(5-11)7-21/h3-6,8-9,23H,1-2H3,(H,22,25)/t9-/m0/s1 |
| InChIKey | SBVBIDUKSBJYEF-VIFPVBQESA-N |
| SMILES | C[C@@H](C(F)(F)F)NS(=O)(=O)C1=CN(C(=C1)C(=O)NC2=CC(=C(C=C2)F)C#N)C |
